Combinatorial targeting of glutamine metabolism and lysosomal-based lipid metabolism effectively suppresses glioblastoma
Yaogang Zhong,Feng Geng,Logan Mazik,Xinmin Yin,Aline Paixao Becker,Shabber Mohammed,Huali Su,Enming Xing,Yongjun Kou,Cheng-Yao Chiang,Yunzhou Fan,Yongchen Guo,Qiang Wang,Pui-Kai Li,Xiaokui Mo,Etienne Lefai,Liqing He,Xiaolin Cheng,Xiang Zhang,Arnab Chakravarti,Deliang Guo
DOI: https://doi.org/10.1016/j.xcrm.2024.101706
2024-08-28
Abstract:Antipsychotic drugs have been shown to have antitumor effects but have had limited potency in the clinic. Here, we unveil that pimozide inhibits lysosome hydrolytic function to suppress fatty acid and cholesterol release in glioblastoma (GBM), the most lethal brain tumor. Unexpectedly, GBM develops resistance to pimozide by boosting glutamine consumption and lipogenesis. These elevations are driven by SREBP-1, which we find upregulates the expression of ASCT2, a key glutamine transporter. Glutamine, in turn, intensifies SREBP-1 activation through the release of ammonia, creating a feedforward loop that amplifies both glutamine metabolism and lipid synthesis, leading to drug resistance. Disrupting this loop via pharmacological targeting of ASCT2 or glutaminase, in combination with pimozide, induces remarkable mitochondrial damage and oxidative stress, leading to GBM cell death in vitro and in vivo. Our findings underscore the promising therapeutic potential of effectively targeting GBM by combining glutamine metabolism inhibition with lysosome suppression.